65,437 trials
Atrial Fibrillation
Primary: Success of Stellate Ganglion Block — 22 Participants
Healthy
Primary: Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of Metformin and Gliclazide — 4974.2507; 8556.7752; 21192.1682; 21815.4021…
Acute Hepatitis C · Human Immunodeficiency Virus · Hepatitis C
Primary: SVR12 (Reinfection Not Considered Failure) — 79 participants
Retinal Degeneration · Primary Open-angle Glaucoma
Primary: Type and Severity of Adverse Effects (AE) and Adverse Reactions (AR) — 1 Participants
COPD · Pulmonary Disease, Chronic Obstructive
Primary: Minutes/Day at 12 Weeks — 1.3125000 minutes/day
Escherichia Coli Infection
Primary: Safety - Occurrence of Adverse Events — 7; 21; 19; 20 Number of Adverse Events
Carotid Artery Diseases
Primary: Safety Evaluation as Composite of Occurrences of Major Stroke, Myocardial Infarction and Death — 0; 0; 0 Occurences
Pulmonary Disease, Chronic Obstructive
Primary: The Number of Observed Patients With First Chronic Obstructive Pulmonary Disease (COPD) Exacerbation to Occur After Cohort Entry — 344; 412; 55; 60 Participants
Major Depressive Disorder
Primary: Pharmacokinetics: Area Under the Plasma Concentration-Time Curve From Time 0 Hour to Infinity (AUC0-∞) of Theophylline — 70200; 78700 nanogram*hour per milliliter…
Parkinson's Disease
Primary: Mean Change in Daily OFF Time From Baseline (Start of Blinded Treatment) to the End of Double-blind Phase (Visit 10) Based on Patient Diaries Using MMRM mITT Population…
Ulcerative Colitis
Primary: Number of Participants With Remission at Week 8 — 0; 1; 2; 1 Participants
Chronic Cough
Primary: Number of Participants Who Experienced an Adverse Event — 9; 2 Participants
Chest Pain · Surgery
Primary: Analgesic Use — 33.35; 35.32 MG
Scleroderma
Primary: Mean Skin Stiffness — 2.68; 2.07; 2.23; 2.27 meters per second — p=0.005
Osteoporosis
Primary: Mean Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) Z-score at Month 12 — 0.582; 0.168 Z-score — p=0.0392